Janux Therapeutics Shares Climb 45% This Week on Deal Speculation
$Janux Therapeutics(JANX.US$ shares climbed for a fifth straight session, poised for a 45% gain this week, after Bloomberg reported that the drugmaker is exploring options, including a potential sale, after receiving takeover interest from larger pharmaceutical companies.
The company, which develops tumor-activated immunotherapies to treat cancer, is working with a financial adviser to evaluate possibilities including a sale, Bloomberg reported midweek, citing people familiar with the matter, who asked not to be identified discussing confidential information.
Discussions are ongoing and there is no guarantee that a deal can be reached, according to the report. The company didn't immediately respond to Bloomberg emails or calls seeking comment.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Moomoo Senior News and Community Manager
Former editor at Bloomberg, then Lazard Asset Management. Posts aren’t investment advice. Views are just mine.
3351Followers
12Following
8196Visitors
Follow